Formulation And Evaluation of Novel Drug Delivery System Containing Anti Parkinson's Agent

Introduction : This study explores the use of buccal administration as a potential route for delivering Levodopa (LD) in the treatment of Parkinson's disease (PD). Parkinson's disease is a neurodegenerative disease that affects dopaminergic neurons, leading to a deficiency of dopamine. The current treatment of choice is levodopa, but it has low oral bioavailability and poor brain uptake. The methodology involves the formulation of buccal mucoadhesive tablets that attach to the buccal mucosa. The study highlights the advantages of the formulation by increasing bioavailability and bypassing of gastrointestinal metabolism. The highly vascularized buccal mucosa allows for direct access to the bloodstream, resulting in high plasma drug concentration and rapid onset of action. The findings suggest that buccal tablet of levodopa will help to relieve Parkinson's disease symptoms. Aim and Objectives : Formulation and evaluation of novel drug delivery system containing anti-parkinson’s agent. To prepare a formulation that will increase the bioavailability of the drug and bypass the first-pass metabolism of the levodopa. Experimental Work : In the present work, a buccal tablet of levodopa was prepared by direct compression method. Different excipients were used to obtain the suitable buccal tablet that passes the criteria for mucoadhesion, swelling and dissolution were used to formulate the buccal tablet. The tablet was evaluated for pre compression parameters for powder blend and post-compression parameters like Hardness, Friability, Mucoadhesive strength, Residence Time, In-vitro dissolution study, and Ex-vivo permeation study. Results : This research has implications for improved bioavailability of drugs and bypasses the gastrointestinal tract. Thus, the prepared Buccal tablets have promising applications for the treatment of Parkinson's Disease. ThePrepared formulation effective for the treatment and the perioperative management of Parkinson's disease patients.